ArticleHaematologica2019
Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Long-term eGFR decline in polycythemia vera compared with secondary polycythemia: a retrospective longitudinal cohort study.Clinical and experimental nephrology · 2026Article
- A Case of Myeloproliferative Neoplasm-Associated Glomerulopathy in a Patient With Myelofibrosis.Clinical case reports · 2025Article
- Renal Impairment in Myeloproliferative Neoplasms: An Under-reported Complication.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.Annals of hematology · 2024Review
- Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia.Advances in hematology · 2024Article
- Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time.Annals of hematology · 2023Article
- Article
- Beneficial effect of ACE inhibitors on kidney function in polycythemia vera.Wiener klinische Wochenschrift · 2021Article
- Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.Annals of hematology · 2020Article
- Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.International journal of hematology · 2020Article
- Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.Cancer chemotherapy and pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.